Treatment Options for Ovarian Cancer: Surgery, Chemo, and Targeted Therapy

If you or someone you love just heard the words "ovarian cancer," your mind is probably racing. What happens next? Is there a plan? Will the treatment be worse than the disease? Those worries are real, and you are not alone in feeling them.
Here is the honest, hopeful truth: ovarian cancer treatment has come a long way. Most people receive a clear, step-by-step plan built around three main tools, surgery, chemotherapy, and targeted therapy, often used together. This guide walks through each one in plain language so you can walk into your next appointment feeling more prepared and less afraid.
This is general education, not personal medical advice. Your care team knows your specific situation best.
How Doctors Build an Ovarian Cancer Treatment Plan
There is no single "right" path. The plan your doctors recommend depends on a few key things:
- The type of ovarian cancer. Most cases are epithelial ovarian cancer, but other, rarer types are treated differently.
- The stage. This describes how far the cancer has spread. Because early symptoms are so vague and there is no reliable routine screening test, most ovarian cancers are found at a later stage, according to the American Cancer Society.
- Your overall health and goals. Age, other health conditions, and whether you hope to preserve fertility all matter.
- Genetic factors. Whether the cancer carries a BRCA gene mutation can open up specific treatment options.
Most people see a gynecologic oncologist, a doctor who specializes in cancers of the female reproductive system. Studies have found that outcomes are often better when this kind of specialist leads care, so it is worth asking for one.
Surgery: Usually the First Step
For most ovarian cancers, surgery is the main treatment, according to the American Cancer Society. It has two goals: to find out exactly how far the cancer has spread (called staging) and to remove as much of it as possible (called debulking or cytoreduction).
Depending on the situation, surgery may involve removing:
- One or both ovaries and fallopian tubes
- The uterus (a hysterectomy)
- The omentum, a fatty layer of tissue in the belly where ovarian cancer often spreads
- Nearby lymph nodes or other tissue with visible cancer
What About Fertility?
This is a deeply personal worry, and it deserves real talk. For some younger people whose cancer is caught very early and is a certain type, it may be possible to remove only the affected ovary and fallopian tube, leaving the uterus and the other ovary in place, according to the American Cancer Society. Whether this is an option depends on the exact type and stage of the cancer. If having children in the future matters to you, raise it before surgery so your team can explore every option.
Surgery and Chemo Together
Sometimes surgery comes first. Other times, doctors give a few rounds of chemotherapy first to shrink the tumor, called neoadjuvant chemotherapy, and then operate. Both approaches are well established. Your surgeon will explain which order makes sense for you and why.
Chemotherapy: Treating Cancer Throughout the Body
Chemotherapy ("chemo") uses drugs to kill cancer cells. Because these drugs travel through the bloodstream, they can reach cancer cells almost anywhere in the body, which is important since ovarian cancer can spread beyond the ovaries.
A few things that often surprise people:
- It is usually a combination. For epithelial ovarian cancer, chemo most often pairs a platinum drug (like carboplatin) with a taxane drug (like paclitaxel). The American Cancer Society notes that two drugs together tend to work better than a single drug as the first treatment.
- It comes in cycles. Treatment for epithelial ovarian cancer typically runs about 3 to 6 cycles, with rest periods in between to let your body recover, according to the American Cancer Society.
- It is usually given through a vein (IV). In some cases, chemo can be delivered directly into the abdomen (called intraperitoneal, or IP, chemotherapy).
Coping With Side Effects
Chemo affects fast-growing healthy cells too, which is why side effects like fatigue, nausea, hair loss, and a higher risk of infection can happen. The encouraging part: many side effects can be managed or eased with supportive medicines, and most fade after treatment ends. Tell your team about anything you feel. You do not have to tough it out in silence.
Targeted Therapy: A Newer, More Precise Approach
Targeted therapy is one of the most hopeful advances in ovarian cancer treatment. Instead of attacking all fast-growing cells the way chemo does, these drugs zero in on specific features that help cancer grow. Two main types are used for ovarian cancer.
PARP Inhibitors
PARP inhibitors (such as olaparib, niraparib, and rucaparib) block a protein that cancer cells use to repair their own damaged DNA. Without that repair system, the cancer cells die.
These drugs can be especially effective for cancers with a BRCA gene mutation, because those cells already struggle to fix DNA damage, according to the American Cancer Society and the National Cancer Institute. In clinical trials, PARP inhibitors used as maintenance therapy after chemotherapy delayed the cancer's return, with the largest benefit in women whose tumors had a BRCA mutation or other DNA-repair problems. This is one reason genetic testing has become such an important part of planning treatment.
Bevacizumab (a VEGF Inhibitor)
Bevacizumab works differently. It blocks signals that tumors use to grow new blood vessels, essentially cutting off the cancer's food supply. The American Cancer Society notes it can slow the growth of advanced epithelial ovarian cancers and often works better when combined with chemotherapy. Unlike some PARP inhibitors, it can be used regardless of BRCA status.
What Happens After Treatment, and If Cancer Returns
Finishing active treatment does not mean you are on your own. Your team will set up regular follow-up visits to watch for any signs the cancer is returning.
If ovarian cancer does come back, that is not the end of the road. There are additional chemo combinations, maintenance options, and treatments designed for recurrent disease. Clinical trials may also offer access to promising new therapies, so ask your oncologist whether one might be a good fit.
And at every stage, palliative care (also called supportive care) can help manage symptoms, pain, and stress. It is not the same as hospice and can be used alongside treatment aimed at curing or controlling the cancer. It is about helping you live as fully and comfortably as possible.
Key Takeaways
- Surgery, chemotherapy, and targeted therapy are the three pillars of ovarian cancer treatment, and they are often used together.
- Surgery usually comes first, to stage the cancer and remove as much of it as possible.
- Chemotherapy typically combines a platinum drug with a taxane and is given in cycles.
- Targeted therapies like PARP inhibitors and bevacizumab attack cancer more precisely; BRCA genetic testing can help guide these choices.
- A gynecologic oncologist should ideally lead your care, and clinical trials and palliative care are valuable options to ask about.
- You have a right to ask questions and to understand every part of your plan.
Questions Worth Asking Your Care Team
- What type and stage of ovarian cancer do I have?
- Will I see a gynecologic oncologist?
- Should I have genetic testing for BRCA or other mutations?
- In what order will surgery and chemo happen, and why?
- Are targeted therapies or clinical trials an option for me?
- What side effects should I expect, and how will we manage them?
You Don't Have to Walk This Alone
Understanding your treatment options is a powerful first step, but it is only that, a first step. Every person's situation is different, and the most important conversation you can have is with a clinician who knows your full history. Bring your questions. Bring a friend or family member. Ask for plain-language explanations until things make sense.
At HopeCare Global, our mission is to make sure no woman is left out of this conversation, especially the women too often overlooked in cancer care. Black women, for example, face higher mortality from ovarian cancer largely because of disparities in diagnosis and access, not biology. Through early-detection education, culturally grounded awareness, and patient navigation, including help finding financial aid and caregiver support, we work to close those gaps. Knowledge, dignity, and support belong to everyone. If you need a starting point, reach out. We are here to help you find your footing.
---
Medical Disclaimer
This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. It does not recommend specific treatments or doses. Always talk with your doctor or a qualified gynecologic oncologist about your individual situation before making any medical decisions. Never disregard or delay seeking professional medical advice because of something you read here.
Sources
- American Cancer Society, Surgery is the main treatment for most ovarian cancers; its goals are staging and debulking (cytoreduction); surgery may remove the ovaries, fallopian tubes, uterus, omentum, and lymph nodes. For certain young, early-stage patients with specific tumor types (e.g., germ cell or stromal), fertility-sparing surgery removing only the affected ovary and fallopian tube may be possible.
- American Cancer Society, Chemotherapy for epithelial ovarian cancer usually combines a platinum drug (cisplatin or carboplatin) with a taxane (paclitaxel or docetaxel), works better as a combination than a single agent, typically runs about 3 to 6 cycles, and is usually given IV (sometimes intraperitoneally).
- American Cancer Society, Targeted therapies for ovarian cancer include PARP inhibitors (olaparib, niraparib, rucaparib) and bevacizumab (a VEGF inhibitor). PARP inhibitors block DNA repair and are especially effective in BRCA-mutated cancers; bevacizumab blocks tumor blood-vessel growth, can slow advanced epithelial ovarian cancer, works better with chemo, and can be used regardless of BRCA status.
- National Cancer Institute, PARP inhibitors used as maintenance therapy after initial chemotherapy delayed cancer progression in advanced ovarian cancer in clinical trials (PRIMA, PAOLA-1, VELIA), with the greatest benefit in women with BRCA mutations or other homologous-recombination-deficient (HRD) tumors.
- American Cancer Society, Because early symptoms are vague and there is no reliable routine screening test, most ovarian cancers are diagnosed at a later stage. (Note: ACS current lifetime risk is now about 1 in 91, updated from the older 1 in 78 figure; the article body no longer states a specific lifetime-risk number.)
- Society of Gynecologic Oncology / peer-reviewed systematic review (Gynecologic Oncology), Ovarian cancer outcomes (including optimal debulking and survival) are often better when care is led by a gynecologic oncologist or provided in a specialized center.
- Peer-reviewed (PMC / Society of Gynecologic Oncology Evidence Review), Black women experience higher ovarian cancer mortality than white women, driven largely by disparities in stage at diagnosis, access to and receipt of guideline-concordant care, and other structural factors rather than biology.
